Design, synthesis, and biological evaluation of AV6 derivatives as novel dual reactivators of latent HIV-1-Reference-Cited by-同舟云学术

Design, synthesis, and biological evaluation of AV6 derivatives as novel dual reactivators of latent HIV-1

Published:2018 Issue:31 Volume:8 Page:17279-17292
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Ao Mingtao¹²³⁴⁵,Pan Zhenrui¹²³⁴⁵,Qian Yuqing¹²³⁴⁵,Tang Bowen¹²³⁴⁵,Feng Zeming¹²³⁴⁵^ORCID,Fang Hua⁶⁴⁵,Wu Zhen¹²³⁴⁵,Chen Jingwei⁷⁸³⁹⁵,Xue Yuhua¹²³⁴⁵,Fang Meijuan¹²³⁴⁵^ORCID

Affiliation:

1. School of Pharmaceutical Sciences

2. Fujian Provincial Key Laboratory of Innovative Drug Target Research

3. Xiamen University

4. Xiamen

5. China

6. The Third Institute of Oceanography of the State Oceanic Administration

7. Key Laboratory for Chemical Biology of Fujian Province

8. College of Chemistry and Chemical Engineering

9. Xiamen 361005

Abstract

As dual-acting HIV LRAs, compounds 12c and 12d could activate latent HIV-1 via the NFAT-required mechanism and as histone deacetylase (HDAC) inhibitors.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Fujian Province

Department of Education, Fujian Province

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2018/RA/C8RA01216D

Reference63 articles.

1. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy